abstract |
The present invention is based on the discovery that the cytoxicity of anti-desmocollin 2 (DSC2) antibodies can be used for treating various cancers including lung, colon, pancreatic, prostate, breast, gastric or liver cancers. Specifically, the present invention provides antibodies against DSC2 that have effector function. Furthermore, the present invention provides methods and pharmaceutical compositions that comprise anti-DSC2 antibody as an active ingredient for damaging DSC2-expressing cells via the effector function of the antibody. |